Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $2.5 million.

  • Fate Therapeutics' Cash from Financing Activities changed N/A to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 9282.47%. This contributed to the annual value of $99.9 million for FY2024, which is 11742000.0% up from last year.
  • Fate Therapeutics' Cash from Financing Activities amounted to $2.5 million in Q3 2025.
  • In the past 5 years, Fate Therapeutics' Cash from Financing Activities ranged from a high of $438.0 million in Q1 2021 and a low of -$180000.0 during Q4 2023
  • Over the past 5 years, Fate Therapeutics' median Cash from Financing Activities value was $2.6 million (recorded in 2022), while the average stood at $35.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 11186.55% in 2023, then skyrocketed by 4602946.86% in 2024.
  • Quarter analysis of 5 years shows Fate Therapeutics' Cash from Financing Activities stood at $3.4 million in 2021, then crashed by 55.62% to $1.5 million in 2022, then plummeted by 111.87% to -$180000.0 in 2023, then surged by 1838.89% to $3.1 million in 2024, then decreased by 20.93% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $1.3 million for Q2 2025, and $3.1 million during Q4 2024.